Vidofludimus hemicalcium

Modify Date: 2024-01-07 15:45:50

Vidofludimus hemicalcium Structure
Vidofludimus hemicalcium structure
Common Name Vidofludimus hemicalcium
CAS Number 1354012-90-0 Molecular Weight 375.40
Density N/A Boiling Point N/A
Molecular Formula C20H18FNO4.1/2Ca Melting Point N/A
MSDS N/A Flash Point N/A

 Use of Vidofludimus hemicalcium


Vidofludimus (4sc-101; SC12267) hemicalcium is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus hemicalcium, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus hemicalcium also can be used for the research of fatty liver by targeting FXR[1][2][3].

 Names

Name Vidofludimus hemicalcium

 Vidofludimus hemicalcium Biological Activity

Description Vidofludimus (4sc-101; SC12267) hemicalcium is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus hemicalcium, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus hemicalcium also can be used for the research of fatty liver by targeting FXR[1][2][3].
Related Catalog
Target

EC50: 450 nM (FXR)[1] IC50: 160 nM (human DHODH)[3]

In Vitro Vidofludimus hemicalcium (0-1 µM) 以浓度依赖性方式选择性激活 FXR,EC50 值约为 450 nM,可诱导各种共激活因子 LXXLL 基序的募集[1]. Vidofludimus hemicalcium (0-8 μM) 通过抑制 IKK-IκB-NF-κB 通路阻断 p65 的核转位[1]。 Vidofludimus hemicalcium 对人 DHODH 具有抑制活性,IC50 值为 160 nM[2]。 Vidofludimus hemicalcium 在体外抑制二氢乳清酸脱氢酶和淋巴细胞增殖[3]。 Vidofludimus hemicalcium 在体外抑制白细胞介素 (IL)-17 分泌,与对淋巴细胞增殖的影响无关[3]。 Vidofludimus hemicalcium 在体外完全阻断 IL-23 + IL-1β 刺激的结肠条分泌 IL-17[3]。
In Vivo Vidofludimus hemicalcium(腹腔注射;每天一次;持续 14 天)在体内以 FXR 依赖性方式对葡聚糖硫酸钠 (DSS) 诱导的结肠炎产生影响[1]。 Vidofludimus hemicalcium(口服;60 mg/kg;持续 6 天)有效改善大鼠 TNBS 诱导的结肠炎的许多参数,并对结肠 STAT3 和 IL-17 具有抑制作用[3]。
References

[1]. Yanlin Zhu, et al. Repositioning an Immunomodulatory Drug Vidofludimus as a Farnesoid X Receptor Modulator With Therapeutic Effects on NAFLD. Front Pharmacol. 2020 May 14;11:590.  

[2]. Andreas Muehler, et al. Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2020 Aug;43:102129.  

[3]. Leo R Fitzpatrick, et al. Vidofludimus inhibits colonic interleukin-17 and improves hapten-induced colitis in rats by a unique dual mode of action. J Pharmacol Exp Ther. 2012 Sep;342(3):850-60.  

 Chemical & Physical Properties

Molecular Formula C20H18FNO4.1/2Ca
Molecular Weight 375.40
Top Suppliers:I want be here

No recommended suppliers.

Hot Compounds More...
Dichloromethane
CAS#:75-09-2
Polyacrylic acid
CAS#:9003-01-4
sodium carbonate
CAS#:497-19-8
Silicon dioxide
CAS#:7631-86-9
Triethanolamine
CAS#:102-71-6
Demeton
CAS#:126-75-0
Water
CAS#:7732-18-5
4-(4-Piperidinyl)morpholine dihydrochloride
CAS#:53617-35-9
Diclofenac sodium
CAS#:15307-79-6
Budesonide
CAS#:51372-29-3